PAHC
Healthcare · Drug Manufacturers - Specialty & Generic
Performance
PAHC (PAHC) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
PAHC (PAHC) operates in the Drug Manufacturers - Specialty & Generic space within the Healthcare sector. With a market cap of $1.3B, it qualifies as a small-cap company. Growth is moderate and the business remains profitable, offering a balanced risk/reward profile compared to high-multiple peers.
- Low P/E of 13.6× suggests the stock may be undervalued relative to earnings
- Forward P/E (9.4×) is lower than trailing P/E (13.6×) — analysts expect earnings to improve
- Revenue growth of 10% YoY shows solid business momentum
- ROE of 30.3% shows management efficiently converts equity into profit
- Current ratio of 3.2× — ample short-term liquidity
- Price is near its 52-week low — potential entry point with asymmetric upside
- Low beta of 0.46 — less volatile than the market, suitable for conservative portfolios
- High debt-to-equity of 217.97× increases financial risk, especially with elevated interest rates
Verdict
Strong Buy
Multiple fundamental strengths with few red flags. Long-term buyers may find this compelling.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Related Articles
Revenue & Results
Dividends
Current DY
1.48%
5Y Avg Annual
$0.4320
Last Payment
$0.1200
Ex-Date
06/03/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest06/03/2026 | 06/24/2026 | $0.1200 | 1.52% |
03/04/2026 | 03/25/2026 | $0.1200 | 1.52% |
11/26/2025 | 12/17/2025 | $0.1200 | 1.52% |
09/03/2025 | 09/24/2025 | $0.1200 | 1.52% |
06/04/2025 | 06/25/2025 | $0.1200 | 1.52% |
03/05/2025 | 03/26/2025 | $0.1200 | 1.52% |
11/27/2024 | 12/18/2024 | $0.1200 | 1.52% |
09/04/2024 | 09/25/2024 | $0.1200 | 1.52% |
Magic Number
Shares needed to self-fund your next purchase
$31.58
Price
$0.1200
Last div. (quarterly)
264
shares
Own 264 PAHC shares ($8,335.80) and each quarterly dividend pays for 1 new share — the snowball runs on its own.
Investment target
$8,335.80
New shares / year
+4 shares
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Earnings
EPS (TTM)
$2.33
P/E (TTM)
13.6
Fwd P/E
9.4
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Key Statistics
Valuation
Trading
Dividends
Profitability
Balance Sheet
Fair Value Estimates
Current price: $31.57
Graham Number
√(22.5 × EPS × Book Value)
$21.62
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$8.00
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
9/10
90% score
Pays dividends
12Y hist.12+ years of dividend history
Dividend consistency (5Y+)
12 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
30.3%Return on equity — measures how efficiently capital is used
Positive profit margin
6.3%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
+10.3%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+15.7%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
217.97×Low financial leverage reduces risk of distress
Current ratio above 1
3.17×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$12M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
1.48%Stock must distribute income to shareholders
Related Assets
Healthcare
About PAHC
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Location
Teaneck, United States
Employees
2,475